Descripción del proyecto
Uso de proteínas de la membrana de las cáscaras de los huevos para curar heridas crónicas
Las heridas crónicas, como las úlceras de las piernas, las úlceras por presión y las úlceras de pie diabético, son heridas que no consiguen curarse en un período de tres meses o heridas que curan sin que se restaure la integridad funcional. Además de que el tiempo de recuperación puede llegar a ser de años o décadas, los pacientes sufren dolores intensos, malestar psíquico y una movilidad limitada. Este proyecto financiado con fondos europeos trabajará en la validación clínica y la producción comercial del innovador apósito DermaRep, que la empresa Biovotec desarrolló recientemente. Este producto novedoso, que se obtiene de la cáscara del huevo y está disponible fácilmente, podría convertirse en un nuevo punto de referencia en la curación de heridas, a la vez que reduce el coste del tratamiento de las heridas crónicas.
Objetivo
A chronic wound (such as Leg Ulcer (LU), Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) can be defined as one that has failed to proceed through an orderly and timely reparative process to produce anatomic and functional integrity within a period of 3 months or that has proceeded through the repair process without establishing a sustained and anatomic and functional result. Chronic wounds may require several years to heal, and some remain unhealed for decades. During this time, patients can experience severe pain, significant emotional and physical distress, reduced mobility and social isolation.
LU, PU and DFU are a major healthcare cost for all developed countries. The main driver for growth in cost is the treatment of chronic and complex wounds in the aging population, complicated by the increase in diabetes and other metabolic disorders. LUs account for $50Bn of global wound care burden in 2015 and are to reach $53Bn in 2020. DFUs account for $52Bn – and are to reach $56Bn by 2020. Further, PUs account for $41Bn of global wound care burden in 2015 – and are to reach $47Bn by 2020.
We have developed an innovative wound dressing, DermaRep™, that is based on biomaterial derived from Eggshell Membrane (ESM) – a by-product readily available in the egg industry. The purified form of ESM is called Purified Eggshell Membrane Protein (PEP).
DermaRep™ is disruptive and will become the benchmark in the wound healing market as it directly addresses the healthcare needs by providing a novel wound care product that is significantly more effective than current Standard of Care (SoC, relatively non-expensive silicon, foam and hydrocolloid dressings) and at least as effective as existing State of the Art (SoA) collagen-based dressings.
Ámbito científico
Programa(s)
Régimen de financiación
IA - Innovation actionCoordinador
0275 OSLO
Noruega
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.